These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22494652)

  • 41. Health economics and outcomes research: informing companion diagnostic development, guidelines, adoption and reimbursement.
    Lee J; Lopez-Rios F
    Expert Rev Mol Diagn; 2013 Jun; 13(5):413-5. PubMed ID: 23782247
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost of cancer care: the patient perspective.
    Kim P
    J Clin Oncol; 2007 Jan; 25(2):228-32. PubMed ID: 17210945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic and cost-effectiveness issues in breast cancer treatment.
    Hillner BE
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Anticancer drugs: Which prices for therapeutic innovations?].
    Gonçalves A; Maraninchi D; Marino P
    Bull Cancer; 2016 Apr; 103(4):361-7. PubMed ID: 27045535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Uptake of breast cancer screening in women aged over 75 years: a controversy to come?
    Eisinger F; Viguier J; Blay JY; Morère JF; Coscas Y; Roussel C; Pivot X
    Eur J Cancer Prev; 2011 Jan; 20 Suppl 1():S13-5. PubMed ID: 21245673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [[How to finance chemotherapy with new cancer drugs?].
    Livartowski A; Beuzeboc P; Le Vu B; Courbard M; Pierga JY; Extra JM; Scholl S; Pouillart P
    Bull Cancer; 2000 Oct; 87(10):745-54. PubMed ID: 11084538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
    Walk EE
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The value proposition of molecular medicine.
    Waldman SA; Terzic A
    Clin Transl Sci; 2012 Feb; 5(1):108-10. PubMed ID: 22376267
    [No Abstract]   [Full Text] [Related]  

  • 50. [Access to cancer care: the cost of treatment matters].
    Tirelli U
    Recenti Prog Med; 2014 May; 105(5):181-3. PubMed ID: 24873939
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular tools for companion diagnostics.
    Zieba A; Grannas K; Söderberg O; Gullberg M; Nilsson M; Landegren U
    N Biotechnol; 2012 Sep; 29(6):634-40. PubMed ID: 22634023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proposal for the breakdown of increased cancer healthcare cost and its improvement.
    Koinuma N
    Jpn J Clin Oncol; 2013 Apr; 43(4):351-6. PubMed ID: 23423810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
    Doble B
    Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New immunotherapies for cancer yield exciting results but high cost.
    Carroll J
    Manag Care; 2013 Oct; 22(10):54-6. PubMed ID: 24350383
    [No Abstract]   [Full Text] [Related]  

  • 55. Economic evaluation of targeted cancer interventions: critical review and recommendations.
    Elkin EB; Marshall DA; Kulin NA; Ferrusi IL; Hassett MJ; Ladabaum U; Phillips KA
    Genet Med; 2011 Oct; 13(10):853-60. PubMed ID: 21637102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA perspective on companion diagnostics: an evolving paradigm.
    Mansfield EA
    Clin Cancer Res; 2014 Mar; 20(6):1453-7. PubMed ID: 24634468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer treatment in US costs more than in Europe but has better outcomes, study says.
    Roehr B
    BMJ; 2012 Apr; 344():e2766. PubMed ID: 22511389
    [No Abstract]   [Full Text] [Related]  

  • 58. The cost of cancer care: part I.
    Eagle D
    Oncology (Williston Park); 2012 Oct; 26(10):918-21, 924. PubMed ID: 23176000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Limiting research on molecular targeted therapies in advanced solid cancers: beyond a cost-effectiveness ratio analysis.
    Nicolini A; Ferrari P; Carpi A
    Biomark Med; 2019 Aug; 13(11):887-890. PubMed ID: 31317773
    [No Abstract]   [Full Text] [Related]  

  • 60. Discussing Health Care Expenses in the Oncology Clinic: Analysis of Cost Conversations in Outpatient Encounters.
    Hunter WG; Zafar SY; Hesson A; Davis JK; Kirby C; Barnett JA; Ubel PA
    J Oncol Pract; 2017 Nov; 13(11):e944-e956. PubMed ID: 28834684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.